MRTX-EX185 formic

• CAT Number: I043568
• Molecular Formula: C34H35FN6O4
• Molecular Weight: 610.68
• Purity: ≥95%
• Synonyms: 4-[4-[(1S,5R)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol;formic acid
• InChI: InChI=1S/C33H33FN6O2.CH2O2/c1-2-20-6-3-7-21-14-24(41)15-25(27(20)21)29-28(34)30-26(16-35-29)31(39-17-22-8-9-23(18-39)36-22)38-32(37-30)42-19-33-10-4-12-40(33)13-5-11-33;2-1-3/h1,3,6-7,14-16,22-23,36,41H,4-5,8-13,17-19H2;1H,(H,2,3)/t22-,23+
• InChIKey: YWOAMEBABPMBDA-ZJXXCOCUSA-N
• SMILES: C#CC1=CC=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5C[C@H]6CC[C@@H](C5)N6)OCC78CCCN7CCC8)O.C(=O)O

MRTX-EX185 formic（Cat No.:I043568）is a potent, selective small-molecule inhibitor targeting KRAS G12D, a common oncogenic mutation found in various cancers, including pancreatic, colorectal, and lung cancers. Unlike earlier KRAS inhibitors focused on G12C, MRTX-EX185 expands therapeutic potential by addressing the G12D mutation with high affinity and specificity. It binds to KRAS G12D in its active state, blocking downstream signaling pathways that drive tumor growth and survival. MRTX-EX185 formic represents a promising advancement in precision oncology and is a valuable tool for studying KRAS-driven tumor biology and targeted cancer therapies.